2010
DOI: 10.1016/j.ijpharm.2009.10.022
|View full text |Cite
|
Sign up to set email alerts
|

Corticosteroid solubility and lipid polarity control release from solid lipid nanoparticles

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
34
0
1

Year Published

2012
2012
2021
2021

Publication Types

Select...
6
3
1

Relationship

0
10

Authors

Journals

citations
Cited by 87 publications
(36 citation statements)
references
References 24 publications
(33 reference statements)
1
34
0
1
Order By: Relevance
“…The mechanism of action of TG includes their binding in human receptor found in skin keratinocytes and fibroblasts [3,63]. Some strategies used to increase the skin delivery of topical glucocorticoids include new vehicles such as metered dose aerosol sprays with hydrofluoroalkane [64] and foams [65], chemical enhancers [66], iontophoresis [35] as well as micro and nanoparticles [11,20,51,67,68].…”
Section: Discussionmentioning
confidence: 99%
“…The mechanism of action of TG includes their binding in human receptor found in skin keratinocytes and fibroblasts [3,63]. Some strategies used to increase the skin delivery of topical glucocorticoids include new vehicles such as metered dose aerosol sprays with hydrofluoroalkane [64] and foams [65], chemical enhancers [66], iontophoresis [35] as well as micro and nanoparticles [11,20,51,67,68].…”
Section: Discussionmentioning
confidence: 99%
“…The logP is a common property of drug molecules used to characterize hydrophobicity of compounds. The influence of logP to drug transport was recognized in many experimental studies in which the mass release was governed by hydrophobicity; there, more hydrophobic compounds (higher logP) were released slower [38]. Consequently, in case drug release from nanoparticle, it can be found that the release process is more dependent on the partitioning of the drug, than on diffusion through the matrix of the nanoparticle [4].…”
Section: Introductionmentioning
confidence: 99%
“…Cyclosporine Liposomes (Freise et al, 1994;Shah et al, 2006); polymeric NP (Gref et al, 2001;Italia et al, 2007;Azzi et al, 2010;Tang et al, 2012); lipid NP (Muller et al, 2008) Preclinical Tacrolimus Lipid NP (Pople and Singh, 2012); polymeric NP (Tammam et al, 2012); liposomes (Erdogan et al, 2002;Zhang et al, 2010) Preclinical Rapamycin/sirolimus Polymeric NP (Yuan et al, 2008;Woo et al, 2012;Shah et al, 2013); micelles (Yanez et al, 2008;Chen et al, 2013); liposomes (Rouf et al, 2009;Ghanbarzadeh et al, 2013) Preclinical Mycophenolic acid Polymeric NP (Shirali et al, 2011); nanogels (Look et al, 2013); dendrimers (Hu et al, 2009) Preclinical Corticosteroids Liposomes Linker et al, 2008;Schweingruber et al, 2011;Ulmansky et al, 2012); polymeric NP (Ishihara et al, 2005;Matsuo et al, 2009); solid lipid NP (Jensen et al, 2010;Zhang and Smith, 2011); dendrimers (Khandare et al, 2005) Preclinical Non-steroidal anti-inflammatory Dendrimers (Chauhan et al, 2004;Na et al, 2006;Chandrasekar et al, 2007;Cheng et al, 2007); nanocolloid (Milkova et al, 2013); lipid NP (Castelli et al, 2005); liposomes (Paavola et al, 2000;Srinath et al, 2000;Turker et al, 2008)…”
Section: Nanocarrier Statusmentioning
confidence: 99%